The National Health Insurance Administration issued a notice today to test the pre-approval system for medical service price projects for high-level new technology and new products. Simply put, before new medical technologies and products are officially put into clinical use, the health insurance department intervenes in advance to carry out price policy evaluations, so that good medical innovations can benefit ordinary people more quickly. The system focuses on supporting three types of high-level innovation: new technologies that have made breakthroughs in diagnosis and treatment, new equipment to solve clinical problems, and new consumables to fill gaps in diagnosis and treatment. However, not all products can be declared. Ordinary iterative upgrade equipment, conventional reagents, and products that can be directly charged according to consumables and drugs are not within the scope of the pre-approved items. The New Deal also imposes restrictions on the price of consumables. For depreciation of medical equipment or medical consumables that account for 60% of the price of the new project, or the price of medical consumables exceeds 5,000 yuan, the health insurance department will urge enterprises to explain the price composition, guide the pricing to match clinical value, take into account the public's ability to pay, and avoid inflated prices for innovative products.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.